AR090587A1 - Compuestos triciclicos sustituidos con actividad hacia los receptores ep1 - Google Patents
Compuestos triciclicos sustituidos con actividad hacia los receptores ep1Info
- Publication number
- AR090587A1 AR090587A1 ARP130101083A ARP130101083A AR090587A1 AR 090587 A1 AR090587 A1 AR 090587A1 AR P130101083 A ARP130101083 A AR P130101083A AR P130101083 A ARP130101083 A AR P130101083A AR 090587 A1 AR090587 A1 AR 090587A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- haloalkyl
- optionally substituted
- hydrogen
- cycloalkyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 15
- 229910052739 hydrogen Inorganic materials 0.000 abstract 6
- 239000001257 hydrogen Substances 0.000 abstract 6
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 4
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 125000002373 5 membered heterocyclic group Chemical group 0.000 abstract 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 abstract 1
- 101150058615 Ptger1 gene Proteins 0.000 abstract 1
- 125000002837 carbocyclic group Chemical group 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 150000003536 tetrazoles Chemical class 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/22—Bridged ring systems
- C07D221/26—Benzomorphans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Procedimiento para su preparación a su uso como medicamento para el tratamiento y/o la profilaxis de enfermedades o trastornos mediados por el receptor EP1 así como a composiciones farmacéuticas que los comprenden. Reivindicación 1: Compuesto de fórmula general (1), en la que: W¹ es un anillo de benceno opcionalmente sustituido con uno o más R² y opcionalmente condensado a un anillo carbocíclico; o un anillo heterocíclico de 5 ó 6 miembros que contiene 1 ó 2 heteroátomos seleccionados de N, O ó S, opcionalmente sustituido con uno o más R²; R es un hidrógeno; o alquilo C₁₋₆; Rᵃ y Rᵇ se seleccionan independientemente de hidrógeno; -OH; -CH₂OH; alquilo C₁₋₆; -O-alquilo C₁₋₆ u -O-haloalquilo C₁₋₆; R¹ es un -COOH; un tetrazol; un -SO₂-NH-C(=O)-R³; un -C(=O)NH-SO₂-R⁴; un -SO₂-OH o un -CN; R² se selecciona independientemente de hidrógeno; halógeno; alquilo C₁₋₆; haloalquilo C₁₋₆; -O-alquilo C₁₋₆; -O-haloalquilo C₁₋₆; cicloalquilo C₃₋₆; -O-cicloalquilo C₃₋₆; -NR⁵SO₂R⁶; fenilo; -CONH₂ o -CN; R³ y R⁴ se seleccionan independientemente de un hidrógeno; alquilo C₁₋₆; un fenilo opcionalmente sustituido; o -N(CH₃)₂; R⁵ y R⁶ se seleccionan independientemente de un hidrógeno; o alquilo C₁₋₆; R⁷ se selecciona de un hidrógeno; alquilo C₁₋₆ o un -COR⁸; R⁸ es un alquilo C₁₋₆; X se selecciona de NR⁷ u O; A es un fenilo opcionalmente sustituido con uno o más sustituyentes seleccionados de alquilo C₁₋₆, halógeno, haloalquilo C₁₋₆, -O-alquilo C₁₋₆, -O-haloalquilo C₁₋₆, -NH-CO-CH₃, un -CN o un cicloalquilo C₃₋₆ opcionalmente sustituido con un alquilo C₁₋₆; o un sistema de anillos o anillo heteroaromático opcionalmente sustituido con uno o más sustituyentes seleccionados de alquilo C₁₋₆, halógeno, haloalquilo C₁₋₆, -O-alquilo C₁₋₆, -O-haloalquilo C₁₋₆, -NH-CO-CH₃, un -CN o un cicloalquilo C₃₋₆ opcionalmente sustituido con un alquilo C₁₋₆; n es 0, 1 ó 2; m es 1 ó 2 ó 3; y las sales, solvatos y profármacos del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12382132.4A EP2647628A1 (en) | 2012-04-02 | 2012-04-02 | Substituted tricyclic compounds with activity towards ep1 receptors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR090587A1 true AR090587A1 (es) | 2014-11-26 |
Family
ID=48040253
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130101083A AR090587A1 (es) | 2012-04-02 | 2013-04-03 | Compuestos triciclicos sustituidos con actividad hacia los receptores ep1 |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP2647628A1 (es) |
| AR (1) | AR090587A1 (es) |
| TW (1) | TW201406728A (es) |
| WO (1) | WO2013149997A1 (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015066612A2 (en) * | 2013-11-03 | 2015-05-07 | The Board Of Trustees Of The University Of Illinois | Cross-coupling of unactivated secondary boronic acids |
| US9657015B2 (en) | 2014-07-31 | 2017-05-23 | Boehringer Ingelheim International Gmbh | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |
| GB201506658D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
| GB201506660D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
| WO2016198908A1 (en) | 2015-06-09 | 2016-12-15 | Abbvie Inc. | Ror nuclear receptor modulators |
| JP6549735B2 (ja) | 2015-06-09 | 2019-07-24 | アッヴィ・インコーポレイテッド | 核内受容体調節剤 |
| RU2018119344A (ru) | 2015-10-26 | 2019-11-28 | Байер Кропсайенс Акциенгезельшафт | Конденсированные бициклические гетероциклические производные в качестве средства для борьбы с вредителями |
| WO2018093569A1 (en) | 2016-11-03 | 2018-05-24 | Bristol-Myers Squibb Company | Substituted bicycle heterocyclic derivatives useful as romk channel inhibitors |
| UY37556A (es) | 2017-01-10 | 2018-07-31 | Bayer Ag | Derivados heterocíclicos como pesticidas |
| EP3568395A1 (de) | 2017-01-10 | 2019-11-20 | Bayer Aktiengesellschaft | Heterocyclen-derivate als schädlingsbekämpfungsmittel |
| BR112019014527A2 (pt) * | 2017-01-23 | 2020-02-27 | Revolution Medicines, Inc. | Compostos de piridina como inibidores de shp2 alostéricos |
| WO2020257753A1 (en) * | 2019-06-20 | 2020-12-24 | Yale University | Phosphatidylserine decarboxylase inhibitors |
| WO2021209689A1 (en) * | 2020-04-17 | 2021-10-21 | Helsingin Yliopisto | Compounds and compositions for treating sweet potato against sweet potato pathogenic viruses |
| WO2022002818A1 (de) | 2020-07-02 | 2022-01-06 | Bayer Aktiengesellschaft | Heterocyclen-derivate als schädlingsbekämpfungsmittel |
| CN114163316B (zh) * | 2021-11-19 | 2024-06-21 | 爱斯特（成都）生物制药股份有限公司 | 一种制备4-溴-2-甲氧基-5-三氟甲基苯甲醛的方法 |
| WO2023105008A1 (en) * | 2021-12-08 | 2023-06-15 | Universität Zürich | Small-molecule inhibitors of the frs2-fgfr interaction |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004072046A2 (en) * | 2003-02-12 | 2004-08-26 | Carex S.A. | Quinoline derivatives and their use for modulation of lxr activity |
| SE0301320D0 (sv) * | 2003-05-06 | 2003-05-06 | Astrazeneca Ab | Positive modulators of nicotinic acetylcholine receptors |
| WO2005016255A2 (en) * | 2003-07-16 | 2005-02-24 | Ligand Pharmaceuticals Incorporated | Substituted tetrahydroquinolines, phenylacetic acids and benzoic acids as hepatocyte nuclear factor 4 (hnf-4 ) modulator compounds |
-
2012
- 2012-04-02 EP EP12382132.4A patent/EP2647628A1/en not_active Withdrawn
-
2013
- 2013-04-02 TW TW102111997A patent/TW201406728A/zh unknown
- 2013-04-02 WO PCT/EP2013/056886 patent/WO2013149997A1/en not_active Ceased
- 2013-04-03 AR ARP130101083A patent/AR090587A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013149997A1 (en) | 2013-10-10 |
| TW201406728A (zh) | 2014-02-16 |
| EP2647628A1 (en) | 2013-10-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR090587A1 (es) | Compuestos triciclicos sustituidos con actividad hacia los receptores ep1 | |
| AR102177A1 (es) | Compuestos de heteroarilo como inhibidores de btk y usos de los mismos | |
| AR119698A2 (es) | Compuesto amida n-urea sustituida derivado de aminoácido | |
| AR106806A1 (es) | Inhibidores triazol de acc y usos de los mismos | |
| CR20160191A (es) | Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4 | |
| AR098136A1 (es) | Compuestos de heteroarilo como inhibidores de btk y usos de los mismos | |
| CU20180144A7 (es) | Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos | |
| MX376271B (es) | Compuestos heterocíclicos y usos de los mismos. | |
| AR098337A1 (es) | Triazolopirazina | |
| AR099177A1 (es) | Determinadas (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1 | |
| AR096979A1 (es) | Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| AR088226A1 (es) | Derivados piperidinicos heterociclicos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades neurodegenerativas | |
| AR100806A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| CL2015002520A1 (es) | Compuestos novedosos de pirimidina y piridina y su uso. | |
| AR088246A1 (es) | Derivados de etinilo | |
| AR100810A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| CU20160192A7 (es) | Derivados de indano e indolina útiles como activadores de la guanilato ciclasa soluble | |
| CR20150378A (es) | Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas | |
| AR094735A1 (es) | Benzamidas sustituidas con actividad hacia receptores ep4 | |
| GT201400167A (es) | Nuevos derivados de bencil sulfonamida utiles como inhibidores de mogat-2 | |
| AR090376A1 (es) | Compuestos herbicidas | |
| AR101479A1 (es) | Derivados de 6-alquinil-piridina | |
| AR100724A1 (es) | Derivados de quinolina y su uso en enfermedades neurodegenerativas | |
| AR099867A1 (es) | Compuestos imidazobenzotiazolo fusionados | |
| AR090588A1 (es) | Compuestos triciclicos sustituidos con actividad hacia los receptores ep1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |